Veradermics, Incorporated
veradermics.comWhat Do They Do?
Develops an extended-release oral treatment candidate for pattern hair loss in men and women.
10-K for FY2025, filed Mar 30, 2026
Sources
Who Are Their Customers?
If approved, the company plans to sell its treatment directly to patients on a cash-pay basis, with access through pharmacies, telehealth, direct mail and provider dispensing.
How Are They Changing?
Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$23.5MView ↗
- ▲ +50% (Loss)
- vs −$15.6M in Q2 FY2025
Loading...
Comments
